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specificity to T2w MRI (reduction of false-positive findings), 
but its main value lies in its direct correlation between the 
choline-to-citrate ratio and tumor aggressiveness.  
mpMRI currently more and more consists of T2w MRI 
combined with DWI. DCE is additionally performed in all 
cases by some institutions, or only in doubtful cases by 
others. Meanwhile, it remains very important that all mpMRI 
studies are performed according to uniform quality and 
reporting standards, as pointed out by the European Society 
of Urogenital Radiology Guidelines and the recently revised 
Prostate Imaging Reporting and Data System (PI-RADS version 
2). The latter consists of a diagnostic probability scale, in 
which PI-RADS 1 and 2 signify “clinically significant disease 
(highly) unlikely”, PI-RADS 3 “clinically significant disease is 
equivocal”, and PI-RADS 4 and 5 signify “clinically significant 
disease (highly) likely”. These scales are largely based on the 
unique ability of mpMRI to more easily detect high-grade and 
larger (i.e. clinically significant) tumors than small lower-
grade lesions. This holds promise in the assessment of 
patients suspected of having prostate cancer. In patients who 
are candidates for active surveillance on the basis of clinical 
parameters, a PI-RADS 1 or 2 scale can corroborate this 
choice owing to a negative predictive value for excluding 
high-grade disease up to 98%, while in patients with a PI-
RADS 4 or 5 a targeted biopsy can be performed in the 
suspicious area, including areas that are more difficult to 
reach with standard biopsy (e.g. anteriorly located tumors). 
PI-RADS 3, on the other hand, requires a biopsy in selected 
cases, taking into account clinical parameters such as PSA-
density, PSA-kinetics, patient age and potential comorbidity. 
Hence, the performance for correctly assigning patients to 
active surveillance can be increased and mpMRI is currently 
recommended at enrolment in active surveillance by the UK 
National Institute for Health and Care Excellence (NICE). 
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Prostate cancer (PCa) is the most common male malignancy. 
The number of diagnoses has increased since the introduction 
of the PSA in the early ‘90ies. Up to 50% of the new PCa 
detected can be considered clinically insignificant or 
indolent: this relatively new concept in oncology means that 
these very well localized, small and non aggressive tumors 
(GPS=3+3), which are generally diagnosed with a biopsy 
following PSA rises, would not cause symptoms and/or death 
during one’s life. Despite this non aggressive behavior, most 
of these tumors are still treated with curative standard 
therapies (prostatectomy, external radiotherapy and 
brachytherapy), which, although equally effective treatment 
options, are burdened by potentially severe side effects.  
As a matter of fact, there is no way to entirely distinguish 
upfront, before as well as after the biopsy, non aggressive, 
clinically insignificant, indolent tumors from aggressive, 
potentially lethal cancers that need to be treated 
immediately. To deal with the problem of overdiagnosis and 
overtreatment, active surveillance (AS) is being proposed in 
alternative to radical treatment to very selected men with 
favourable disease characteristics. AS is widely accepted in 
uro-oncologic communities and included in several 
guidelines, even if its routine application in the clinic is still 
suboptimal.  
Understanding the natural history of clinically insignificant 
PCa is of primary importance to obtain reliable tools to select 
and follow-up AS patients. AS inclusion criteria are presently 
based on ≤T2a at DRE, PSA/PSA density, number and 
percentage of positive biopy cores and GPS. Originally, the 
approach was more restrictive (i.e. selection of very low risk 
PCa patients). Nowadays, considering that feasibility and 
safety of these more strict protocols were assessed, more 
inclusive protocols are enrolling patients (e.g. including 
selected GPS=3+4).  
One of the main issues AS is currently facing is the chance of 
“inadequate” diagnoses from biopsies, known to result in 
upgrading and upstaging at prostatectomy, especially for low-
grade PCa. PSA/PSA density or the number of positive cores 
at diagnostic biopsy do not appear to be associated with the 
probability of upgrading patients initially fit for AS. This is 
the main reason to consider a confirmatory biopsy (time 
varying between 3 and 12 months) in most AS protocols, 
which can help identify patients ineligible for AS as a result 
of disease upgrading. The rate of “reclassification” at 
confirmatory biopsy varies between 16 and 30%, very similar 
to the one after prostatectomy.  
Due to its great potential, MRI is increasingly used, being able 
to identify lesions that might be missed by standard biopsy. A 
positive MRI is associated to higher upgrading rates after 
prostatectomy and also after confirmatory biopsy. At 
present, in men on AS, MRI is used as an aid to detect 
clinically significant disease and help target suspicious 
lesions; however, there is still no solid evidence to endorse 
MRI in place of repeated biopsies.  
Investigation on genetic/biomolecular/biochemical signatures 
is urgently needed to better classify our patients, trying to 
take benefit from non-invasive indicators of progression or 
reclassification. Research is currently focused on finding 
genetic signatures of both positive biopsy and adjacent 
normal tissue/stroma and on studying biomolecular markers 
possibly present in urine and blood (liquid biopsy). Recently, 
tests based on high expression of selected genes in biopsy 
specimens were found to be associated with higher risk of 
disease progression, but the possible true impact on AS is still 
to be determined.  
AS follow-up plays a crucial role, since it enables to monitor 
the tumor behavior and potentially detect the more 
aggressive forms, which may benefit from treatment. In most 
protocols, follow up is based on clinical data (DRE, PSA and 
repeat biopsies), some protocols recently including mpMRI. 
Biomarkers (e.g. PCA3 or -2proPSA) are not routinely used in 
AS protocols, due to confusing results coming from the 
literature.  
In conclusion, the results of AS programs should be primarily 
assessed on their ability to avoid overtreatment, while 
guaranteeing the same curability window of upfront radical 
treatments. The percentage of patients who remain 
treatment free is one of these measures, with current 
estimates being ≈40% at 20 years from diagnosis. Evaluation 
of oncological outcomes such as OS and CSS rates is also 
important, being in the Canadian AS cohort 62% and 94% at 15 
yrs, respectively. Secondary objectives should include 
quality-of-life and comparison of AS vs radical therapies 
costs. The variety of inclusion criteria and follow-up 
protocols makes the evaluation difficult. However, to date, 
the published outcomes are similar to those in patients 
receiving immediate curative treatment. 
 
Symposium: Achieving excellence in image guided 
brachytherapy  
 
 
SP-0107  
Physician training in contouring 
P. Petric
1National Center for Cancer Care & Research A member of 
Hamad Medical Corporation, Doha, Qatar 
1 
 
In the past 2-3 decades we have witnessed major advances of 
radiotherapy planning. These developments were based on 
implementation of sectional imaging, computerized 
treatment planning and high precision treatment 
technologies in the radiotherapy process. When compared 
with the conventional radiography based method, modern 3-4 
dimensional approaches require accurate and reproducible 
delineation of the target volume and organs at risk on the 
sectional images of various modalities, including computed 
tomography, magnetic resonance imaging, positron emission 
tomography and ultrasound. Contouring variation represents 
one of the most important contributors to the overall 
uncertainties in radiotherapy. The dosimetric and clinical 
benefits of modern high precision radiotherapy can be 
compromised by inaccurate delineation [Njeh CF. Med Phys 
2008]. Assurance of consistent and accurate contouring of the 
regions of interest is one of the main preconditions for safe 
